

UTERINE MYOMAS

- I. Pathophysiology
 - Exact etiology unclear, thought to develop from smooth muscle cells, metaplastic transformation of connective tissue cells, or persistent embryonic nest cells
 - Hormonally responsive to estrogen; grow during pregnancy and regress with menopause
 - Classified as submucosal (beneath endometrium), intramural (in uterine wall, most common), or subserosal (beneath serosa)
 - May outgrow blood supply and degenerate causing pain
- II. Epidemiology
 - 30-40% of American women will have one by age 40
- III. Risk Factors
 - African American women have a 3-9 times higher risk
- IV. Presentation
 - 50-65% of women are without symptoms
 - Abnormal uterine bleeding manifested as menorrhagia, leading to anemia
 - Pressure related symptoms (pelvic pressure, fullness, heaviness), constipation, urinary retention
 - Infertility (responsible for 2-10% of infertility cases as fibroids distort canal and tubes)
 - Pain if vascular compromise occurs
- V. Physical Exam
 - On bimanual exam, the uterus is non-tender but irregularly enlarged and “lumpy-bumpy”
- VI. Differential Diagnoses
 - Endometrial hyperplasia or carcinoma
 - Endometriosis or adenomyosis
 - Uterine sarcomas
 - Pregnancy
 - Ovarian cyst or neoplasm
 - Tubo-ovarian abscess
- VII. Evaluation
 - Pelvic ultrasound most commonly done, but other tests include MRI, HSG, hysteroscopy
- VIII. Treatment
 - Most don't require treatment and can be managed expectantly, Follow the mass size and growth
 - It is very important to r/o other causes of pelvic masses (i.e. cancer)
 - If causing severe pain, infertility, urinary tract symptoms, or showing evidence of post-menopausal growth treat either medically or surgically
 - A. Medical treatment – medroxyprogesterone, danazol, GnRH agonists all shrink fibroids by decreasing estrogen. However, when drug is d/c fibroids often resume growth. Drugs may be used temporarily in peri-menopausal women until endogenous estrogen decreases naturally.
 - B. Surgical indications –
 - i. abnormal uterine bleeding causing anemia
 - ii. severe pelvic pain secondary to amenorrhea
 - iii. size > 12 wks gestation obscuring evaluation of adnexa
 - iv. urinary frequency or retention
 - v. growth after menopause
 - vi. infertility
 - vii. rapid increase in size (r/o leiomyosarcoma)
 - C. Myomectomy – Good for patients who want to preserve their fertility but the fibroid will recur in 50% of patients
 - D. Hysterectomy – The definitive treatment. Perform oophorectomy only if ovaries are damaged or age > 45 y/o